Article
Oncology
Chengcheng Gong, Qin Xiao, Yi Li, Yajia Gu, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Yannan Zhao, Yizhao Xie, Xichun Hu, Biyun Wang
Summary: The study revealed that ERP occurred in more than half of patients with metastatic breast cancer treated with everolimus, and was associated with improved treatment outcomes.
Article
Pharmacology & Pharmacy
Camille Moreau-Bachelard, Marie Robert, Carole Gourmelon, Emmanuelle Bourbouloux, Anne Patsouris, Jean-Sebastien Frenel, Mario Campone
Summary: Everolimus is an oral drug that inhibits mTOR with immunosuppressive and antiproliferative characteristics. It is commonly used in association with exemestane in hormone receptor (HR)-positive advanced breast cancer (ABC). This review summarizes the publications relating to everolimus in breast cancer and highlights its efficacy and tolerability, particularly in patients who have previously been treated with aromatase inhibitors (AI).
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Oncology
Maria Spiliotaki, Galatea Kallergi, Christos Nikolaou, Nikolaos Xenidis, Eleni Politaki, Stella Apostolaki, Nefeli Georgoulia, Filippos Koinis, Nikolaos Tsoukalas, Dora Hatzidaki, Athanasios Kotsakis, Vassilis Georgoulias
Summary: The study demonstrates that the combination of E/E treatment can lead to early elimination of proliferating CTCs in mBC patients, which is associated with a favorable clinical outcome.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, Valerie Seegers, Monica Arnedos, Delphine Loussouarn, Qing Wang, Laurence Vanlemmens, Marta Jimenez, Maria Rios, Veronique Dieras, Agnes Leroux, Gilles Paintaud, Keyvan Rezai, Fabrice Andre, Maeva Lion, Jean-Louis Merlin
Summary: Adding everolimus to preoperative trastuzumab did not improve efficacy but induced MAPK signaling in HER2-positive early operable breast cancer patients. Combination therapy should be considered to maximize the effectiveness of trastuzumab in this setting.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Article
Oncology
Wei-Pang Chung, Wei-Lun Huang, Chun-Hui Lee, Hui-Ping Hsu, Wan-Ling Huang, You-Yu Liu, Wu-Chou Su
Summary: The activation of the PI3K signaling pathway is associated with the development and resistance of breast cancer. Mutations in PIK3CA and loss of PTEN occur in all subtypes of breast cancer. The combination of PI3K inhibitors and trastuzumab shows potential in treating HER2-positive breast cancer, but its effectiveness in HER2-positive breast cancer with PIK3CA mutations and/or PTEN loss is still unclear. In this study, a novel alpha isoform-specific PI3K inhibitor was shown to effectively target breast cancer cells with PIK3CA mutations or PTEN deficiency when combined with trastuzumab. The combination therapy was found to be ineffective in breast cancer cells without PI3K pathway alterations, indicating a biomarker-specific treatment. In vivo testing in a mouse model confirmed the efficacy of the combination therapy in reducing tumor volume. This cytotoxic chemotherapy-free regimen, as a biomarker-driven strategy, warrants further investigation for the treatment of HER2-positive breast cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang
Summary: This study compared the efficacy and safety between novel anti-human epidermal growth factor receptor 2 antibody-drug conjugates (ADCs) and trastuzumab emtansine for patients with tyrosine kinase inhibitor (TKI) treatment failure. The results showed that both T-Dxd and other novel anti-HER2 ADCs had significantly better progression-free survival and objective response rate than T-DM1, with tolerable toxicities.
Article
Medicine, Research & Experimental
Lie Chen, Cui-Cui Liu, Si-Yuan Zhu, Jing-Yu Ge, Yu-Fei Chen, Ding Ma, Zhi-Ming Shao, Ke-Da Yu
Summary: This multiomics study provides insights into the molecular characteristics and therapeutic strategies of hormone receptor-negative and HER2-low breast cancer, identifying three distinct subgroups and potential therapeutic targets for this subtype.
Article
Oncology
Samitha Andrahennadi, Amer Sami, Kamal Haider, Haji Ibraheem Chalchal, Duc Le, Osama Ahmed, Mita Manna, Ali El-Gayed, Philip Wright, Shahid Ahmed
Summary: The study found that fulvestrant is effective in both early and later lines of treatment, with better outcomes in the early treatment group. Women with visceral organ diseases had lower disease control and survival rates on fulvestrant. Those who received chemotherapy after fulvestrant and showed clinical response had better survival.
Article
Oncology
S. A. E. Kitano, A. K. I. K. O. Honda, N. A. O. K. O. Itoi, T. E. C. C. H. U. U. Lee
Summary: This study retrospectively reviewed the efficacy of everolimus as a post-treatment option following CDK4/6 inhibitor therapy in 13 breast cancer patients. The results showed that everolimus can prolong progression-free survival and has a certain clinical benefit rate.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Aleix Prat, Fara Braso-Maristany, Olga Martinez-Saez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galvan, Debora Martinez, Tomas Pascual, Mercedes Marin-Aguilera, Anna Rodriguez, Nuria Chic, Barbara Adamo, Laia Pare, Maria Vidal, Mireia Margeli, Ester Ballana, Marina Gomez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sanchez-Bayona, Anna Sunol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Munoz, Blanca Gonzalez-Farre, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Summary: This study uses shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in metastatic breast cancer patients. Machine learning multi-gene signatures obtained from ctDNA can identify complex biological features similar to those obtained from direct tumor tissue DNA or RNA profiling.
NATURE COMMUNICATIONS
(2023)
Letter
Medicine, General & Internal
Sreeram V. Ramagopalan, Riccardo Pisoni, Lokendra Singh Rathore, Joshua Ray, Cormac Sammon
Summary: This cohort study compares the efficacy of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with the results of the CLEOPATRA trial.
Article
Oncology
Jin Su Kim, Jae Min Cho, Hyeongi Kim, Youn Kyoung Jeong, Jong-Ki Kim, Eun Ho Kim
Summary: The combination of TTFields and TRZ can enhance TRZ penetration and strengthen its effect after inducing apoptosis through TTFields therapy, overcoming tumor resistance to TRZ.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Multidisciplinary Sciences
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
Summary: According to this study, pyrotinib combined with chemotherapy is more effective than lapatinib combined with chemotherapy in terms of PFS and ORR for patients with HER2-positive metastatic breast cancer, but it carries higher safety risks.
